文献速递神经核医学

随访123I-FP-CIT多巴胺转运体SPECT在临床不确定帕金森综合征诊断中的效用

Utility of Follow-up Dopamine Transporter SPECT With 123I-FP-CIT in the Diagnostic Workup of Patients With Clinically Uncertain Parkinsonian Syndrome.
PubMed 文献 · Clin Nucl Med · 2017-01-01

该研究纳入3个中心的141例患者,基线FP-CIT SPECT后22.4±13.7个月进行随访SPECT,由2名有经验阅片者按7点评分回顾性判读。基线正常或典型帕金森病(PD)减少型者随访均确认原分类;基线轻度不确定者72%随访出现异常、20%明显进展。作者认为完全正常或典型PD减少者不宜常规推荐随访SPECT,<60岁者亦不推荐,且无证据支持延迟随访超过12个月。

要点

  • 基线FP-CIT SPECT完全正常或呈典型PD减少型者,随访SPECT均确认原分类,不推荐常规随访。
  • 基线轻度不确定者中72%随访出现异常、20%明显进展,但<60岁者明显进展非常罕见。
  • 作者认为无证据支持将随访FP-CIT SPECT延迟至12个月以上。

核心结论

  • 完全正常基线SPECT或典型PD减少型者,随访FP-CIT SPECT不能普遍推荐。
  • 年龄<60岁者即使基线SPECT存在轻度不确定,也不推荐随访FP-CIT SPECT。
  • 无证据支持将随访FP-CIT SPECT延迟超过12个月。

研究设计与样本

  • 来自3个中心的141例患者(65.1±10.4岁),在基线SPECT后22.4±13.7个月接受随访FP-CIT SPECT。
  • 由2名有经验阅片者按7点评分对FP-CIT SPECT进行回顾性视觉判读。

主要发现

  • 基线FP-CIT SPECT正常或PD特征性减少的病例(n=58),随访SPECT均确认原分类。
  • 基线存在轻度不确定的病例(n=65)中,72%随访SPECT显示异常,20%显示提示黑质纹状体变性的明确进展。
  • 年龄<60岁者中出现上述明显进展非常罕见。
  • 最终分类为正常或神经退行性变不受基线至随访SPECT时间间隔的影响。

关键数值与推荐

  • 7点评分包括:正常、因轻度不对称或轻至中度均匀减低所致某种轻度不确定、PD减少型1/2/3型、非典型减少。

临床怎么用

  • 作者认为完全正常基线SPECT或典型PD减少型者不能普遍推荐随访FP-CIT SPECT。
  • 作者认为年龄<60岁者即使基线SPECT存在轻度不确定,也不推荐随访FP-CIT SPECT。
  • 作者认为无证据支持将随访FP-CIT SPECT延迟超过12个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Dopamine transporter SPECT with I-FP-CIT is registered for detection (or exclusion) of nigrostriatal degeneration to support the etiologic classification of parkinsonian syndromes. In case of uncertainty in the interpretation of SPECT findings or unexpected clinical course, follow-up SPECT might be useful. However, the utility of follow-up FP-CIT SPECT has not yet been clarified. METHODS: One hundred forty-one patients (65.1 ± 10.4 years) from 3 sites with follow-up FP-CIT SPECT 22.4 ± 13.7 months after baseline SPECT were included. Retrospective visual interpretation of FP-CIT SPECT scans was performed by 2 experienced readers according to the following 7-point score: "normal," some minor degree of uncertainty due to "mild asymmetry" or mild to moderate "uniform reduction," "Parkinson disease (PD) reduction type 1/2/3," and "atypical reduction." RESULTS: Normal FP-CIT SPECT or PD characteristic reduction was confirmed by follow-up SPECT in all cases (n = 58). Among patients with some minor degree of uncertainty at baseline (n = 65), the majority (72%) did now show abnormalities in follow-up SPECT, but 20% showed clear progression suggesting nigrostriatal degeneration. The latter was very rare at age younger than 60 years. The final categorization as normal or neurodegenerative was not affected by the time delay between baseline and follow-up SPECT. CONCLUSIONS: Follow-up FP-CIT SPECT cannot be generally recommended in case of completely normal baseline SPECT or PD characteristic reduction. It also cannot be recommended in patients younger than 60 years, even in case of some minor degree of uncertainty in the baseline SPECT. There is no evidence to delay follow-up FP-CIT SPECT longer than 12 months.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Apostolova I, Taleb DS, Lipp A, et al. Utility of Follow-up Dopamine Transporter SPECT With 123I-FP-CIT in the Diagnostic Workup of Patients With Clinically Uncertain Parkinsonian Syndrome. Clin Nucl Med. 2017. PMID: 28574876. doi:10.1097/RLU.0000000000001696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。